Milad Abolhasani

ALCOA Professor and University Faculty Scholar

Milad Abolhasani is an ALCOA Professor and a University Faculty Scholar in the Department of Chemical and Biomolecular Engineering at North Carolina State University. He received his Ph.D. from the University of Toronto in 2014. Prior to joining NC State University, he was an NSERC Postdoctoral Fellow in the Department of Chemical Engineering at MIT (2014-2016). At NC State University, Dr. Abolhasani leads a diverse research group that studies self-driving labs tailored toward accelerated discovery, development, and manufacturing of advanced functional materials and molecules using fluidic micro-processors. Dr. Abolhasani has received numerous awards and fellowships, including NSF CAREER Award, AIChE 35 Under 35, Dreyfus Award for Machine Learning in the Chemical Sciences & Engineering, Scialog Fellowship, AIChE NSEF Young Investigator Award, I &EC Research 2021 Class of Influential Researchers, AIChE Futures Scholar, ALCOA Research Achievement Award, ACS-PRF Doctoral New Investigator Award, and Emerging Investigator recognition from Nanoscale, Lab on a Chip, Reaction Chemistry & Engineering, and Journal of Flow Chemistry.

Russ B. Altman

The Kenneth Fong Professor of Bioengineering, Genetics, Medicine, & Biomedical Data Science, and, by courtesy, Computer Science Senior Fellow, Stanford Institute for Human-Centered AI, Stanford University

Russ Biagio Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science, Senior Fellow at the Stanford Institute for HAI, and past chairman of the Bioengineering Department at Stanford University. His research applies computing (informatics, data science and AI) to problems relevant to medicine. He is interested in methods for understanding drug action, efficacy and adverse effects while integrating molecular, cellular, organism and population data. His lab has a special focus on how human genetic variation impacts drug response—pharmacogenomics. He is the founding Principal Investigator of the Pharmacogenomics Knowledgebase (PharmGKB.org). He helps lead an FDA-supported Center of Excellence in Regulatory Science & Innovation, and is an Associate Director of the Stanford Institute for Human-Centered Artificial Intelligence.  Dr. Altman holds an AB from Harvard College, an MD from Stanford Medical School, and a PhD in Medical Information Sciences from Stanford. He received the U.S. Presidential Early Career Award for Scientists and Engineers and a National Science Foundation CAREER Award. He is a fellow of the American College of Physicians (ACP), the American College of Medical Informatics (ACMI), the American Institute of Medical and Biological Engineering (AIMBE), and the American Association for the Advancement of Science (AAAS). He is a member of the National Academy of Medicine. He is a past-president, founding board member, and a fellow of the International Society for Computational Biology (ISCB), and a past-president of the American Society for Clinical Pharmacology & Therapeutics (ASCPT). He has chaired the Science Board advising the FDA commissioner, served on the NIH Director’s Advisory Committee, and co-chaired the IOM Drug Forum. He is an organizer of the annual Pacific Symposium on Biocomputing, and a founder of Personalis (NASDAQ: PSNL). Dr. Altman is board certified in Internal Medicine and in Clinical Informatics. He directed the Stanford Biomedical Informatics training program from 2000-2018, and currently directs the undergraduate major in Biomedical Computation. He received the Stanford Medical School graduate teaching awards in 2000 & 2020 and its mentorship award in 2014. He received the Stanford Alumni Association Kornberg-Berg Lifetime Achievement Award in 2023. He is the founding editor of the Annual Reviews of Biomedical Data Science, and hosts a podcast entitled “The Future of Everything.”

Rommie Amaro

Professor of Molecular Biology, Distinguished Professorship in Computational and Theoretical Chemistry, University of California, San Diego

Rommie E. Amaro holds the Distinguished Professorship in Theoretical and Computational Chemistry at the University of California, San Diego. She grew up on the south side of Chicago and received her B.S. in Chemical Engineering (1999) and her Ph.D. in Chemistry (2005) from the University of Illinois at Urbana-Champaign. Rommie was a NIH postdoctoral fellow with Prof. J. Andrew McCammon at UC San Diego from 2005-2009, and started her independent lab at the University of California, Irvine in 2009. In 2011 she moved to UC San Diego. She is the recipient of an NIH New Innovator Award, the Presidential Early Career Award for Scientists and Engineers, the ACS COMP OpenEye Outstanding Junior Faculty Award, the ACS Kavli Foundation Emerging Leader in Chemistry, the Corwin Hansch Award, and the 2020 ACM Gordon Bell Special Prize for COVID19. Rommie’s scientific interests lie at the intersection of computer-aided drug discovery and biophysical simulation. Her scientific vision revolves around expanding the range and complexity of molecular constituents represented in atomic-level molecular dynamics simulations, the development of novel multiscale methods for elucidating their time dependent dynamics, and the discovery of novel chemical matter controlling biological function.

Cheryl Arrowsmith

CSO, Structural Genomics Consortium, University of Toronto

Cheryl Arrowsmith is a Senior Scientist at the Princess Margaret Cancer Centre, Professor in the Department of Medical Biophysics, University of Toronto, and the Chief Scientist of the Structural Genomics Consortium (SGC) at the University of Toronto. Her research focuses on the structural and chemical biology of chromatin and epigenetic regulatory factors especially as relates to cancer and drug discovery. In partnership with major pharmaceutical companies, she leads the SGC’s international open science program that is developing and distributing unencumbered Chemical Probes that support the discovery of new medicines. She received her Ph.D. from the University of Toronto and carried out postdoctoral research at Stanford University, and was co-founder of Affinium Pharmaceuticals, which developed a new medicine for multidrug resistant bacteria. She has published over 300 research articles, and was recognized by Clarivate Analytics as being among the worlds top 1% of highly cited scientists in 2018, 2019 and 2022, 2023. She was elected a AAAS Fellow (2015), and a Fellow of the Royal Society of Canada (2020).

David Baker

HHMI investigator, professor of biochemistry, and director of the Institute for Protein Design, University of Washington School of Medicine

David Baker is the director of the Institute for Protein Design, a Howard Hughes Medical Institute Investigator, a professor of biochemistry, and an adjunct professor of genome sciences, bioengineering, chemical engineering, computer science, and physics at the University of Washington. His research group is focused on the design of macromolecular structures and functions. Dr. Baker has published over 600 research papers, been granted over 100 patents, and co-founded 21 companies. Over 80 of his mentees have gone on to independent faculty positions.

David received his PhD in biochemistry with Randy Schekman at UC Berkeley and did postdoctoral work in biophysics with David Agard at UCSF. Dr. Baker is a recipient of the Breakthrough Prize in Life Sciences and is a member of the National Academy of Sciences and the American Academy of Arts and Sciences.

Stephen K. Burley

University Professor and Henry Rutgers Chair

Stephen Kevin Burley is an expert in data science and bioinformatics, structural biology, and structure-guided drug discovery for oncology. He is the Director of the RCSB Protein Data Bank (RCSB.org). Within Rutgers, The State University of New Jersey he serves as University Professor and Henry Rutgers Chair, Founding Director of the Institute for Quantitative Biomedicine, and Cancer Pharmacology Research Program Co-Leader within the Rutgers Cancer Institute of New Jersey. Burley’s previous roles were Distinguished Lilly Research Scholar, Eli Lilly and Co.; Chief Scientific Officer and Senior Vice President for Research, SGX Pharmaceuticals, Inc.; Richard M. and Isabel P. Furlaud Professor, The Rockefeller University; and Investigator, Howard Hughes Medical Institute. His degrees include M.D. - Harvard Medical School; D.Phil. - Oxford University; and B.Sc. (physics) and Doctor of Science (Honoris causa) - Western University. Burley has published extensively in data science and bioinformatics, artificial intelligence/machine learning, structural biology, and clinical oncology.

John D. Chodera

Member, Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center

The Chodera Lab is developing the infrastructure to enable fully autonomous small molecule drug discovery powered by next-generation hybrid physical/machine learning models to predict potency, selectivity, and resistance in a data-efficient manner. We develop advanced predictive computational methodologies for drug discovery in frontier areas where these models are lacking, working with industry collaborators to deploy those solutions in real drug discovery programs. We build open source tools---such as OpenMM, which has been downloaded over 1.2 million times, run on millions of machines, and powers advances such as AlphaFold---that enable these algorithms to have impact across the drug discovery and biomolecular modeling fields. We create open science communities---such as (1) the Open Force Field Initiative, (2) the COVID Moonshot (which delivered a patent-free COVID antiviral preclinical candidate into an IND-enabling preclinical program funded by the Wellcome Trust), (3) the Folding@home Consortium which harnesses hundreds of thousands of volunteer computers around the world to accelerate biomolecular simulation and discovery, and (4) the AI-driven Structure-enabled Antiviral Program that received $68M in initial funding from the NIH for open science antiviral drug discovery. We apply these tools to cancer, where we develop models for (1) designing small molecule kinase inhibitors with targeted polypharmacology, (2) predicting drug sensitivity or resistance of clinical mutations, and (3) understanding the detailed structural mechanisms underlying oncogenic mutations. And we train the next generation of interdisciplinary scientists equipped to tackle the most challenging problems in health and human disease for industrial drug discovery.

Connor W. Coley

Assistant Professor, Massachusetts Institute of Technology

Connor W. Coley is the Class of 1957 Career Development Professor and an Assistant Professor at MIT in the Department of Chemical Engineering and the Department of Electrical Engineering and Computer Science. He received his B.S. and Ph.D. in Chemical Engineering from Caltech and MIT, respectively, and did his postdoctoral training at the Broad Institute. His research group at MIT works at the interface of chemistry and data science to develop models that understand how molecules behave, interact, and react and use that knowledge to engineer new ones, with an emphasis on therapeutic discovery. Connor is a recipient of C&EN’s “Talented Twelve” award, Forbes Magazine’s “30 Under 30” for Healthcare, Technology Review’s 35 Innovators Under 35, the NSF CAREER award, the ACS COMP OpenEye Outstanding Junior Faculty Award, the Bayer Early Excellence in Science Award, the 3M NTFA, and was named a Schmidt AI2050 Early Career Fellow and a 2023 Samsung AI Researcher of the Year.

Sean Ekins

CEO, Collaborations Pharmaceuticals, Inc.

Sean Ekins Ph.D., D.Sc. is founder and CEO of Collaborations Pharmaceuticals, Inc. which is focused on developing and using machine learning and AI approaches for rare and neglected disease drug discovery. Sean graduated from the University of Aberdeen; receiving his M.Sc., Ph.D. in Clinical Pharmacology and D.Sc. in Science. He was a postdoc at Eli Lilly then senior scientist at Pfizer, then served at increasing levels of responsibility in several start-up pharma and software companies (Concurrent, GeneGo, CDD and Phoenix Nest) as well as scientific advisor for several rare disease foundations (PHRF, HNF). He has authored or co-authored >370 peer reviewed papers, book chapters, edited 5 books on different aspects of drug discovery research as well as authored a new book on ‘Winning Grants’. His interests include the dual use of AI and coverage of his research has also appeared in the Economist, Financial Times, Washington Post and appears in a Netflix documentary “Unknown: Killer Robots”.

Martha S. Head (Marti)

Executive Director, Computational and Data Sciences, Amgen Inc.

Martha S. Head (Marti) is Executive Director of Computational and Data Sciences at Amgen, where she leads a team applying mechanistic, machine-learning, and AI computational methods to the understanding of disease biology and the discovery and design of biologic and synthetic therapeutics. Previously, she was at Oak Ridge National Laboratory (ORNL), where she was Director of Computational Biomedical Initiatives and Director of the Joint Institute for Biological Sciences, a collaborative research effort between and the University of Tennessee system. Before joining ORNL, Dr. Head spent 20 years in R&D at GlaxoSmithKline Pharmaceuticals (GSK). For many of those years, Dr. Head led GSK’s U.S. Computational Chemistry team, whose accountability was to proactively and creatively apply all relevant computational tools to progressing drug discovery efforts from target selection through to selection of a candidate for clinical trials. Dr. Head led GSK’s collaboration with Palantir, a Silicon Valley data integration and exploration company, and built GSK’s Insights from Data team. Dr. Head received her PhD in physical chemistry from Duke University in 1995.

Joel Karpiak

Head of Data and Predictive Sciences, GSK

Joel joined GSK in 2015 from UCSF, where he focused on large-scale modeling and virtual screening for orphan GPCRs.  Initially working in small molecule design for over 5 years, he transitioned over into growing the Protein Design & Informatics group for the past 3 years.  In this role, he championed how data can be generated and used to drive structure- and machine learning-based design of reagents, biocatalysts, and therapeutic proteins to support new ways of working in discovery and development.  Now leading the newly formed Data and Predictive Sciences organization that centralizes data science, computational design, and enterprise systems and data standards, Joel’s team enables a smooth flow of quality, model-ready experimental and in silico data for re-use across GSK R&D.

Shyam Rele

Program Officer and Sr. Subject Matter Expert, BARDA

Shyam Rele, PhD has 23+ years of experience at the interface of Biotech, Manufacturing and Outsourcing operations, Federal Research Enterprise, Non-profits, Academia and Management Consulting. Over the course of his tenure, he has led the execution, scientific and strategic operations management of a diverse portfolio of projects catering to Phase-appropriate translational and integrated Clinical Product development lifecycle, CMC development and GMP manufacturing of Drug substance and Drug product (Phase 1, 2) at CDMOs, process development and scale-up, nonclinical studies, analytical/assay development and characterization, formulation development for vaccines, biologics/therapeutics, adjuvants and small molecule drug APIs. In addition, Dr. Rele is a KOL and has specialized know how of translational development of drug delivery systems/formulations; advanced biomanufacturing technologies; nano-molding and roll-to-roll fabrication technologies; and development of cost-effective process development and prototypes. Dr. Rele, has spearheaded development of corporate and federal product strategy and new programs/initiatives, IP-enabling innovation development for nanoparticle/microparticle delivery and formulation systems.

Currently, Dr. Rele, is a Program Officer and Senior Interdisciplinary Expert at Biomedical Advanced Research and Development Authority (BARDA). At BARDA, he provides scientific and strategic expertise on cross-BARDA development programs, and technologies/platforms/tools to advance the mission of pandemic preparedness/response and address emerging health security threats. He plays a pivotal role in advancement of Project Next-Gen COVID-19 and Pandemic Flu mRNA vaccines and therapeutics product development and manufacturing campaigns; flexible on-demand biomanufacturing and capability development initiatives; enabling development of drug delivery technologies; evaluation of innovative and adaptable solutions for vaccine/therapeutics; pathogen-agnostic host-directed therapeutics and proactive immunity; and facilitate development of Target product/platform profiles to guide new medical countermeasure development. As a key opinion leader, Dr Rele, has serves as a core member on Office of Director initiated cross-BARDA special projects, DRIVe/BARDA market shaping team, inter/intra cross Government agency working groups and BARDA Ventures to assess and analyze emerging technologies and portfolio products.

Joni L. Rutter

Director, NCATS

Joni L. Rutter, Ph.D., is the director of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). She oversees the planning and execution of the Center’s complex, multifaceted programs that aim to overcome scientific and operational barriers impeding the development and delivery of new treatments and other health solutions. Under her direction, NCATS supports innovative tools and strategies to make each step in the translational process more effective and efficient, thus speeding research across a range of diseases, with a particular focus on rare diseases. By advancing the science of translation, NCATS helps turn promising research discoveries into real-world applications that improve people’s health. In her prior role as the NCATS deputy director, Rutter collaborated with colleagues from government, academia, industry, and nonprofit patient organizations to establish robust interactions with NCATS programs.

During her career, Dr. Rutter has earned a national and international reputation for her diverse and unique expertise via her journal publications and has received several scientific achievement awards, including the 2022 Rare Disease Legislative Advocates, RareVoice Award—Federal Advocacy and the 2022 FedHealthIT—Women in Leadership Impact Award.

Marissa Saunders

Senior Director, Data Science, Recursion Pharmaceuticals

Dr. Saunders has oriented her career around using AI and ML to answer impactful questions, using technology to turn data into insights. She is currently a Senior Director of Data Science at Recursion with a mission of using AI to decode biology in order to radically improve lives. In this role, she leads teams that sit at the interface between deep learning and drug program teams, leveraging the embeddings and data from DL models to accelerate discovery and decision-making for programs in a cross-program focused way. These teams use automated 'omics experiments, AI and ML predictions and analyses, and standardized workflows and decision engines to enable drug discovery at scale. Prior to Recursion, she worked in the learning space, using language models to develop a taxonomy of skills, and as a big-data data science consultant, working in fields ranging from biotech to video games.

She received her PhD in Chemistry from the University of Chicago, focusing on understanding how protein movement can be correlated with function, and did a post doc at the University of Utah in a structural biology lab, turning cryoEM images into protein structures and relating these structures to protein function.

Gisbert Schneider

Full Professor at the Department of Biosystems Science and Engineering, ETH Zürich

Gisbert Schneider is a full professor of Computer-Assisted Drug Design at ETH Zurich, where he spearheads research into integrating artificial intelligence and machine-learning methods into contemporary drug discovery. His career spans from the Pharmaceuticals Division at Roche to academia, initially at Goethe University in Frankfurt before assuming his current position at ETH Zurich. From 2021 to 2023, he served as the Director of the Singapore-ETH Centre at the CREATE campus. Gisbert is esteemed as an elected Fellow of the University of Tokyo. He is credited with introducing the concept of AI-based drug design to medicinal chemistry and is renowned for coining the term "scaffold hopping". His extensive body of work includes over 450 scientific papers. Additionally, he has co-founded several startup companies and serves as a consultant to the chemical and life science industry. Gisbert’s contributions to medicinal chemistry have garnered widespread acclaim, evidenced by numerous prestigious awards, including the Ernst Schering Prize, Herman Skolnik Award, and the Gmelin-Beilstein Medal.

Kimberly Sciarretta

BARDA

Kimberly Sciarretta, Ph.D., is the Acting Director of the Division of Research and Ventures (DRIVe), part of the Biomedical Advanced Research and Development Authority (BARDA), and the Branch Chief for DRIVe’s Launch Office. In her role, Dr. Sciarretta leads the Host-Based Diagnostics, Host-Directed Therapeutics, and the Decentralized Clinical Operations for Healthcare and Research (D-COHRe) programs. Dr. Sciarretta has been with BARDA since 2015 and was one of the inaugural members of DRIVe, influencing the vision and growth of the Division. Before BARDA, Dr. Sciarretta had extensive experience within the Department of Defense and other U.S. Government Agencies as a technical consultant, focusing on biological and chemical defense and leading innovation in areas including synthetic biology and advanced manufacturing. Dr. Sciarretta strives to build and pilot new strategic approaches to support agile preparedness for public health emergencies and improve patient outcomes. Dr. Sciarretta received her Ph.D. in Molecular Genetics and Cell Biology from the University of Chicago.

Woody Sherman

Chief Innovation Officer, Psivant Therapeutics

Woody Sherman is founder and Chief Innovation Officer at Psivant Therapeutics. Prior roles included Chief Computational Scientist at Roivant Sciences, Chief Scientific Officer at Silicon Therapeutics, and Global Head of Applications Science at Schrodinger. Woody received his B.S. in Physical Chemistry and B.A. in Creative Studies from the University of California at Santa Barbara (UCSB). He then completed his Ph.D. at MIT working in Professor Bruce Tidor’s lab, jointly between the departments of Physical Chemistry and The Computer Science and Artificial Intelligence Lab (CSAIL). Woody has published over 100 peer-reviewed papers on a broad range of topics, including molecular dynamics, quantum mechanics, free energy simulations, enhanced sampling, virtual screening, induced-fit docking, protein design, small molecule optimization, machine learning, cheminformatics, hybrid ligand/structure-based methods, pharmacophore modeling, and more. Additionally, Woody is an Adjunct Professor at the University of Massachusetts at Amherst (UMass) where he gives lectures on computational chemistry, drug design, innovation, and company creation.

Bryn Taylor

PhD. Scientist, In Silico Discovery, Johnson & Johnson Innovative Medicine

Dr. Taylor joined J&J Innovative Medicine after completing her PhD in Biomedical Sciences at the University of California San Diego in 2020, where she used methods from computational chemistry and biology to study the effects of therapeutics on human proteins and entire microbiomes. At J&J, Dr. Taylor works on early-stage drug development for difficult targets in oncology, with a focus on using computational tools to advance modalities such as targeted protein degradation. She is a member of the Biophysical Society Theory and Computation Executive Council and is a member and cofounder of Therapeutics Discovery and Discovery Chemistry DEI Councils at J&J IM.

Alexander Tropsha

KH Lee Distinguished Professor, UNC Eshelman School of Pharmacy, UNC Chapel Hill

Alexander Tropsha, PhD. is K.H. Lee Distinguished Professor at the UNC Eshelman School of Pharmacy, UNC-Chapel Hill. Prof. Tropsha obtained his PhD in Chemical Enzymology in 1986 from Moscow State University, Russia. His research interests are in the areas of Computer-Assisted Drug Design, Cheminformatics, Computational Toxicology, Materials Informatics, Structural Bioinformatics, and Biomedical Knowledge Graph Mining. He has authored or co-authored over 300 peer-reviewed research papers, reviews, and book chapters. His research has been supported by multiple grants from the NIH, NSF, EPA, DOD, research foundations, and private companies. He is an elected Fellow of the American Institute for Medical and Biological Engineering (AIMBE) and a consultant to several technology and drug discovery companies. He is a co-founder of Predictive, LLC, a UNC startup specializing in building models and tools for chemical toxicity prediction.

Alexandre Varnek

Professor, University of Strasbourg (France)

Alexandre Varnek is a full professor in theoretical chemistry, head of the Laboratory of Chemoinformatics and the director of the MSc program in chemoinformatics at the University of Strasbourg, France. He also is a PI of the Chemoinformatics group at ICReDD (Hokkaido University, Japan). He published 3 books and > 300 research articles and book chapters. He is an Editor-in Chief of the journal “Molecular Informatics (WILEY). His research focuses on chemoinformatics and molecular modeling.

Alexey Zakharov

Informatics Group Leader, NCATS

Alexey Zakharov is the informatics group leader in an early therapeutic discovery project team within NCATS’ Division of Preclinical Innovation, where he manages and coordinates the team’s efforts to achieve project deliverables and milestones. The main goal of his group research program is to utilize computational methods and ML/AI-based approaches to accelerate screening and discovery campaigns, and to contribute comprehensive analysis and modeling techniques to data generated for small molecule development projects. He oversees the proper application of cheminformatics techniques and targeted molecular design to deliver compounds with improved properties, having better selectivity and safety margins. Alexey Zakharov is involved in more than 50 active probe discovery projects focused on cancer and cardiovascular, neurological, viral and inflammatory diseases. He received his PhD in bioinformatics from the Institute of Biomedical Chemistry of the Russian Academy of Medical Sciences in 2008.

Barbara Zdrazil

ChEMBL Coordinator, Chemical Biology Services, European Bioinformatics Institute (EMBL-EBI)

Barbara Zdrazil is a scientific leader with ~15 years of experience in cheminformatics and computational drug discovery with an academic track record and international reputation. She currently works as ChEMBL group coordinator at the European Bioinformatics Institute (EMBL-EBI) in Hinxton, Cambridge, UK. Prior to this role, Barbara was a group leader at the Department of Pharmaceutical Sciences, University of Vienna, Austria, and worked as a Consultant for Open Targets. Barbara is also an Editor of Journal of Cheminformatics since 2020.

Barbara received her PhD (Pharmaceutical Chemistry) from the University of Vienna, performed her postdoctoral training at the Heinrich Heine University of Düsseldorf and accomplished her Venia Docendi (Pharmacoinformatics) at the University of Vienna. Her current scientific focus is to aid in the delivery of AI-ready small molecule drug discovery data, lower the barriers to efficient data usage globally, and automate data extraction and curation processes without loss in data quality.

Alex Zhavoronkov

Founder and CEO, Insilico Medicine

Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine, a leading clinical-stage biotechnology company developing next-generation generative artificial intelligence and robotics platforms for drug discovery. Since 2014, he has invented critical technologies in the field of generative artificial intelligence and reinforcement learning (RL) for the generation of novel molecular structures with the desired properties and the generation of synthetic biological and patient data. Under his leadership, Insilico raised over $400 million in multiple rounds from expert biotechnology, healthcare, and financial investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Since 2021, the company nominated 18 preclinical candidates, started 6 human clinical trials, and entered Phase II with an AI-discovered novel target and AI-designed novel molecule.

Since 2012, he has published over 200 peer-reviewed research papers and 3 books. He serves on the advisory or editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, and Frontiers in Genetics, and founded and co-chairs the Annual Aging Research and Drug Discovery (10th Annual in 2023). He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.